RxDoctor Payments DataLook up a doctor →

Sarah Merritt, MD

Pain Medicine · Bowie, MDNPI 1730303777

Payments from drug & device makers

$22,313in general payments, 2019–2025

Across 421 payments — averaging $53.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • MDD US Operations, LLC$6K
  • Collegium Pharmaceutical, Inc.$5K
  • Biodelivery Sciences International, Inc.$2K
  • AbbVie$2K
  • Saluda Medical Americas, Inc.$1K
  • Medtronic$911
  • plus $5K from 41 others

What the payments were for

  • Consulting fees$1,2005%
  • Speaking & faculty fees$10,12545%
  • Travel & lodging$1,1405%
  • Food & beverage$9,83244%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,313 in reported general payments places this provider in the 85th percentile of 144 pain medicine providers in Maryland.

See all pain medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$533,317
Medicare patients
438
Services billed
12,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate42$21,648
OxycontinOxycodone Hcl23$13,990
MovantikNaloxegol Oxalate13$5,093
Lidocaine36$4,857
Oxycodone Hcl205$4,098
Fentanyl43$3,646
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl13$3,134
Morphine Sulfate ErMorphine Sulfate61$2,563
Pregabalin65$2,428
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen97$2,235
Gabapentin111$1,170
Diclofenac Sodium28$1,054
Hydromorphone Hcl65$871
Duloxetine Hcl39$834
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen31$722

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$4,978$21,64842 claims
Redhill Biopharma Inc.Movantik$165$5,09313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 144 pain medicine providers in Maryland.

Other pain medicine in Bowie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →